Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Brensocatib Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.PMN.303

    Clinical Policy: Brensocatib (Brinsupri)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PMN.303 alerts

    Get alerted when Policy CP.PMN.303 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage of Brensocatib (Brinsupri) for Ambetter members with non-cystic fibrosis bronchiectasis. It applies to commercial, HIM/ICHRA, and Medicaid lines of business, subject to applicable state Medicaid requirements.

    Policy Summary
    PayerAmbetter Nevada
    PolicyBrensocatib (Brinsupri) coverage
    Policy CodePolicy CP.PMN.303
    Change TypeAnnual review clarification and administrative update
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit clinical documentation supporting all applicable approval criteria for Brensocatib.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage requires that the member does not have cystic fibrosis for non-cystic fibrosis bronchiectasis.

    The health insurance marketplace/ICHRA line of business was added to the policy.

    12 monthsApproval duration
    25 mg/dayMaximum dose
    2 adults / 1 pediatricExacerbations required
    12 yearsMinimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10 mg or 25 mgTablet strengths

    Coverage Criteria

    Initial therapy – non-cystic fibrosis bronchiectasis

    Covered for non-cystic fibrosis bronchiectasis when all of the following are met.

    Initial approval – non-cystic fibrosis bronchiectasis

    • Diagnosis: Chest computed tomography (CT) confirms bronchiectasis and the member does not have cystic fibrosis.

      Both components are required.

    • Prescriber and age: The medication is prescribed by or in consultation with a pulmonologist, and the member is at least 12 years old.≥ 12 years
    • Supportive therapy: The provider attests that the member is currently receiving optimal supportive therapy, such as airway-clearance techniques, pulmonary rehabilitation, mucoactives, or antibiotics.

      Examples are not exhaustive.

    • Exacerbation history

      • Adults: The member is age 18 years or older and has had at least 2 pulmonary exacerbations requiring systemic antibiotics in the last 12 months.≥ 2 in the last 12 months
      • Pediatrics: The member is age 12 through 17 years and has had at least 1 pulmonary exacerbation requiring systemic antibiotics in the last 12 months.≥ 1 in the last 12 months
    • Smoking status: The member is not an active smoker, evidenced by a negative nicotine metabolite test, specifically cotinine, obtained within the last 30 days.Negative test within 30 days
    • Comorbidity and dose: The member does not have a primary diagnosis of asthma or chronic obstructive pulmonary disease, and the dose does not exceed 25 mg (1 tablet) per day.≤ 25 mg (1 tablet) per day

      Secondary or comorbid diagnoses of asthma or chronic obstructive pulmonary disease are allowable.

    Continuation therapy – non-cystic fibrosis bronchiectasis

    Continued coverage for non-cystic fibrosis bronchiectasis requires all of the following.

    Continuation therapy

    • Benefit or continuity eligibility

      • Established approval: The member is currently receiving the medication through the Centene benefit or previously met initial approval criteria.
      • Continuity of care: The member is currently receiving the medication and is enrolled in a state and product with continuity-of-care regulations.

        Refer to the applicable state-specific continuity-of-care addenda.

    • Response: The member is responding positively to therapy.

    Other diagnoses or indications

    Other diagnoses or indications must meet one of the following pathways.

    • Recent label change: If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, refer to the applicable no-coverage-criteria policy for formulary or PDL drugs, or the applicable non-formulary policy for drugs not on the formulary or PDL.Within the last 6 months

      Use the policy applicable to the member’s line of business.

    • Off-label pathway: If the requested use is not specifically listed under the diagnoses or indications for which coverage is not authorized, and the recent-label-change pathway does not apply, refer to the applicable off-label-use policy.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label-use policy or evidence-of-coverage documents.

    Clinical Thresholds and Limits

    Adult pulmonary exacerbations
    Required thresholdAt least 2 pulmonary exacerbations
    Antibiotic requirementEach exacerbation must require systemic antibiotics
    Look-back periodIn the last 12 months
    Pediatric pulmonary exacerbations
    Eligible age groupPediatrics ages 12 to 17 years
    Required thresholdAt least 1 pulmonary exacerbation
    Antibiotic requirement and timeframeRequiring systemic antibiotics in the last 12 months

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization

    Submit an initial prior authorization request with documentation showing that the member meets all approval criteria for Brinsupri (brensocatib). Initial approval is for 12 months.

    • Non-cystic fibrosis bronchiectasis confirmed by chest CT, with no cystic fibrosis.
    • Prescription by or consultation with a pulmonologist; member is age ≥ 12 years.
    • Current optimal supportive therapy, qualifying pulmonary exacerbation history, and a recent negative cotinine test.
    • No primary diagnosis of asthma or chronic obstructive pulmonary disease; secondary/comorbid diagnoses are allowable.
    • Dose does not exceed 25 mg (1 tablet) per day.
    Prior Authorization

    Continuation Prior Authorization

    For continuation requests, submit evidence that the member remains eligible for therapy and is responding positively. Continuation approval is for 12 months.

    Therapy Background

    Brensocatib (Brinsupri) is a dipeptidyl peptidase 1 inhibitor indicated for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 years and older.

    Coverage applies to members with CT-confirmed bronchiectasis who continue to experience clinically significant pulmonary exacerbations despite optimal supportive therapy.

    Definitions

    Pulmonary exacerbation
    DefinitionWorsening of 3 or more major symptoms over 48 hours
    Treatment consequenceResults in a healthcare provider’s decision to prescribe systemic antibiotics
    Major symptomsMay include increased cough, sputum changes or purulence, breathlessness, decreased exercise tolerance, fatigue or malaise, and hemoptysis
    DPP1 inhibitor
    Drug classDipeptidyl peptidase 1 inhibitor
    AbbreviationDPP1 inhibitor
    Policy context

    Initial Therapy

    Initial therapy

    Initial therapy for non-cystic fibrosis bronchiectasis requires all approval criteria.

    • Diagnosis: Chest CT confirms bronchiectasis and the member does not have cystic fibrosis.
    • Prescriber and age: The medication is prescribed by or in consultation with a pulmonologist, and the member is at least 12 years old.
    • Supportive therapy: The provider attests that the member is currently receiving optimal supportive therapy.
    • Exacerbation history

    Continued Therapy

    Continued therapy

    Continued therapy is covered when all criteria are met.

    • Benefit or continuity eligibility

      • Established approval: The member is currently receiving the medication through the Centene benefit or previously met initial approval criteria.
      • Continuity of care: The member is currently receiving the medication and is enrolled in a state and product with continuity-of-care regulations.

        Refer to the applicable state-specific continuity-of-care addenda.

    • Response: The member is responding positively to therapy.

    Quantity Limits

    Brensocatib (Brinsupri)
    MedicationBrensocatib (Brinsupri)
    Maximum quantity25 mg per day
    Tablet limit1 tablet per day
    Policy Summary
    PayerAmbetter Nevada
    PolicyBrensocatib (Brinsupri) coverage
    Policy CodePolicy CP.PMN.303
    Change TypeAnnual review clarification and administrative update
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit clinical documentation supporting all applicable approval criteria for Brensocatib.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and LimitsPrior Authorization and DocumentationTherapy BackgroundDefinitionsInitial TherapyContinued TherapyQuantity Limits
    Dose increase: If the request is for a dose increase, the new dose does not exceed 25 mg (1 tablet) per day.≤ 25 mg (1 tablet) per day
    Optimal supportive therapy duration
    Minimum durationAt least 3 months
    Therapy requirementOptimal supportive therapy
    Clinical contextQualifying exacerbations must occur despite optimal supportive therapy
    Negative cotinine test
    Test requiredNegative nicotine metabolite test, specifically cotinine
    Testing timeframeObtained within the last 30 days
    Status establishedMember is not an active smoker
    Age
    Minimum ageAt least 12 years
    Pediatric rangeAges 12 to 17 years
    Adult thresholdAdults are age 18 years or older
    Maximum dose
    Maximum daily dose25 mg per day
    Tablet limit1 tablet per day
    Available dosing regimen10 mg or 25 mg by mouth once daily
    • Document that the member is currently receiving Brinsupri through a Centene benefit or previously met initial approval criteria, or is receiving the medication under applicable state and product continuity-of-care regulations.
    • Document positive clinical response to therapy.
    • For a dose increase, document that the new dose does not exceed 25 mg (1 tablet) per day.
    Documentation Required

    General Clinical Documentation

    Provider documentation must support that the member has met all applicable approval criteria. Submit office chart notes, laboratory results, or other relevant clinical information with the request.

    • Include records supporting the diagnosis, prescriber or specialist involvement, age, supportive therapy, exacerbation history, smoking status, comorbid conditions, treatment response when applicable, and requested dose.
    Documentation Required

    Diagnosis and Treatment Documentation

    Document non-cystic fibrosis bronchiectasis and the treatment history supporting the request.

    • Provide a chest CT report confirming bronchiectasis.
    • Document that the member does not have cystic fibrosis.
    • Provide a pulmonologist prescription or consultation, and document that the member is at least 12 years old.
    • Attest that the member is currently receiving optimal supportive therapy, such as airway-clearance techniques, pulmonary rehabilitation, mucoactives (including nebulized hypertonic saline, mannitol, dornase alfa, or acetylcysteine), and/or antibiotics (including oral azithromycin or erythromycin, or inhaled tobramycin or aztreonam).
    Documentation Required

    Exacerbation History

    Document the qualifying pulmonary exacerbation history despite at least 3 months of optimal supportive therapy. Each qualifying exacerbation must require systemic antibiotics.

    • Adults age ≥ 18 years: at least 2 pulmonary exacerbations in the last 12 months.
    • Pediatrics age 12–17 years: at least 1 pulmonary exacerbation in the last 12 months.
    • Include dates, clinical records, and antibiotic treatment information supporting each qualifying exacerbation.
    Documentation Required

    Smoking-Status Testing

    Document that the member is not an active smoker with a negative nicotine-metabolite test obtained within the 30 days before the request.

    • Submit the recent negative cotinine test result.
    Denial Risk

    Initial Eligibility Failure Risks

    The request may be denied when required diagnostic, specialist, age, or supportive-therapy criteria are not met.

    • Bronchiectasis is not confirmed by chest CT or the member has cystic fibrosis.
    • The medication is not prescribed by or provided in consultation with a pulmonologist.
    • The member is younger than 12 years.
    • The member is not currently receiving optimal supportive therapy.
    • Required qualifying exacerbation history despite at least 3 months of optimal supportive therapy is not documented.
    Denial Risk

    Response, Smoking, Comorbidity, and Dose Failure Risks

    Authorization may be denied when the member has an active-smoking result, a disqualifying primary comorbidity, inadequate continuation response, or an excessive dose.

    • The member has a positive or missing required recent cotinine test and therefore is not documented as a nonsmoker.
    • The member has a primary diagnosis of asthma or chronic obstructive pulmonary disease; secondary or comorbid asthma or chronic obstructive pulmonary disease is allowable.
    • For continuation, positive response to therapy is not documented or the member does not meet the applicable ongoing-therapy or continuity-of-care pathway.
    • The requested dose, including an increased dose, exceeds 25 mg (1 tablet) per day.
    Denial Risk

    Unaddressed or Non-FDA-Approved Use

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy unless sufficient documentation of efficacy and safety supports the use under the applicable off-label policy or evidence-of-coverage document.

    • For commercial coverage, refer to CP.CPA.09.
    • For health insurance marketplace/ICHRA coverage, refer to HIM.PA.154.
    • For Medicaid coverage, refer to CP.PMN.53 or the applicable evidence-of-coverage documents.
    Brensocatib (Brinsupri) is a DPP1 inhibitor
    Adults:
    Age 18 years or older with at least 2 pulmonary exacerbations requiring systemic antibiotics in the last 12 months.
  1. Pediatrics: Age 12 through 17 years with at least 1 pulmonary exacerbation requiring systemic antibiotics in the last 12 months.
  2. Smoking status: The member is not an active smoker, evidenced by a negative nicotine metabolite or cotinine test obtained within the last 30 days.
  3. Comorbidity and dose: The member does not have a primary diagnosis of asthma or chronic obstructive pulmonary disease, and the dose does not exceed 25 mg (1 tablet) per day.

    Secondary or comorbid diagnoses of asthma or chronic obstructive pulmonary disease are allowable.

  4. Dose increase: If the request is for a dose increase, the new dose does not exceed 25 mg (1 tablet) per day.